Lexaria Bioscience Corp. (LEXX)
| Market Cap | 16.87M |
| Revenue (ttm) | 175,268 |
| Net Income (ttm) | -6.98M |
| Shares Out | 5.95M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,538 |
| Open | 2.75 |
| Previous Close | 2.83 |
| Day's Range | 2.75 - 2.87 |
| 52-Week Range | 1.85 - 7.20 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 13.01 (+358.9%) |
| Earnings Date | Jul 21, 2022 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for oral... [Read more...]
Financial Performance
In 2021, LEXX's revenue was $722,738, an increase of 129.59% compared to the previous year's $314,793. Losses were -$4.19 million, 2.49% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for LEXX stock is "Buy." The 12-month stock price forecast is 13.01, which is an increase of 358.91% from the latest price.
News
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that do...
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Pro...
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that it...
Why Shares Of Lexaria Biosciences Are Trading Higher
Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology. The first agreement is a manufacturing operating agreem...
Lexaria Grants License to AnodGen Bioceuticals
DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 8, 2022 /...
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has s...
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the...
Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 ...
Lexaria Grants License to Valcon Medical for the European Market
Contract Manufacturing Organization first in Europe to License DehydraTECH Lexaria will receive milestone fees and royalty payments from product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria B...
Lexaria Announces 2022 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 20...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trust...
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
Lexaria Bioscience Corp (NASDAQ: LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States...
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" ...
Lexaria Commences Multi-Week Human Clinical Hypertension Study
HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits This study is designed to enhance Lexaria's probabilities of success with its expe...
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. The post Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Why Lexaria Shares Are Rising Today
Lexaria Bioscience Corp (NASDAQ: LEXX) said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-process...
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug A...
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria B...
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new...
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to c...
Lexaria Granted Important New Oral Nicotine Patent
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global inno...
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexa...
Lexaria Provides Annual Letter From the CEO
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an a...
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2 " KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" o...
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug ...
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has ente...